Rates of overweight and obesity have more than doubled in the United States during the last three decades, according to a new analysis. By 2050, it’s anticipated that 213 million adults (age, > 25 ...
GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women among the most common users. Despite their high use in this group, women ...
Long-term GLP-1 use slows medical cost growth, according to findings published Jan. 13 from professional services firm Aon. The firm analyzed 192,000 GLP-1 users from July 2022 to March 2025, ...
The World Anti-Doping Agency (WADA) said it is now monitoring GLP-1 use among elite athletes, including at the Winter Olympics in Italy. Being ‘monitored’ does not mean a substance is prohibited; ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Women who used a GLP-1 before pregnancy were more likely ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Diabetes management-dose GLP-1 use reduces recurrent ...
A new report based on national prescription data shows weight-loss drug use is rising among kids and teens. GLP-1 medications, like Ozempic and Wegovy, are drugs originally developed to treat diabetes ...
About one in eight U.S. adults (12%) say they are currently taking a GLP-1 medication such as Ozempic or Wegovy for weight loss, diabetes, heart disease or another chronic condition, a new KFF Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results